c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma
published in: European Journal of Haematology
date of publication: 2020-03-07
main subject: dexamethasone
Cites articles 48
- 2018-02-22
- 2014-09-01
Date
Title
Article - wd:Q90126528